Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial

被引：182

作者：

Ahn, M. -J. ^{[1
]}

Yang, J. ^{[2
]}

Yu, H. ^{[3
]}

Saka, H. ^{[4
]}

Ramalingam, S. ^{[5
]}

Goto, K. ^{[6
]}

Kim, S. -W. ^{[7
]}

Yang, L. ^{[8
]}

Walding, A. ^{[9
]}

Oxnard, G. R. ^{[10
]}

机构：

[1] Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Sect Hematol Oncol, Seoul, South Korea

[2] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[3] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA

[4] Japanese Natl Hosp Org, Nagoya Med Ctr, Resp Med & Med Oncol, Nagoya, Aichi, Japan

[5] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA

[6] Natl Canc Ctr East, Dept Thorac Oncol, Chiba, Japan

[7] Univ Ulsan, Sch Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea

[8] AstraZeneca, Global Med Dev, Oncol, Shanghai, Peoples R China

[9] AstraZeneca, Patient Safety, Macclesfield, Cheshire, England

[10] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA

来源：

关键词：

D O I：

10.1016/S1556-0864(16)30246-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

1360

引用

页码：S115 / S115

页数：1